4U4.F Laekna, Inc.

Healthcare Biotechnology Frankfurt Exchange
0.7400 EUR
Close of Nov 11, 2026
0.6050 1.97
Market cap
EUR 334M
P/E
-
P/B
2.06x
ROE
-19.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4U4.F undervalued?

Graham number

The Graham number of Laekna, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Laekna, Inc. fundamental analysis

No fundamental analysis for Laekna, Inc. yet.

Laekna, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Laekna, Inc.

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking human…

Full company profile